Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 12/20 | 1.00 |
| ▸ | SRC | P12931 | 10/20 | 0.80 |
| ▸ | LCK | P06239 | 9/20 | 0.80 |
| ▸ | TEK | Q02763 | 8/20 | 0.80 |
| ▸ | FLT3 | P36888 | 7/20 | 0.80 |
| ▸ | KDR | P35968 | 4/20 | 0.80 |
| ▸ | EGFR | P00533 | 3/20 | 0.80 |
| ▸ | FYN | P06241 | 2/20 | 0.80 |
| ▸ | LYN | P07948 | 2/20 | 0.80 |
| ▸ | CSK | P41240 | 2/20 | 0.80 |
| ▸ | BTK | Q06187 | 2/20 | 0.80 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.80 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.80 |
| ▸ | ABL1 | P00519 | 2/20 | 0.80 |
| ▸ | PLK4 | O00444 | 1/20 | 0.80 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.80 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.80 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.80 |
| ▸ | PAK4 | O96013 | 1/20 | 0.80 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752471 | 1.00 | HCK (1.00) | HCKSRCLCKTEKFLT3 | |
| SCHEMBL21283026 | 0.95 | HCK (0.90) | HCKSRCLCKTEKFLT3 | |
| SCHEMBL6461460 | 0.91 | HCK (0.83) | HCKSRCLCKTEKFLT3 | |
| SCHEMBL6468049 | 0.91 | HCK (0.83) | HCKSRCLCKTEKFLT3 | |
| SCHEMBL6461457 | 0.91 | HCK (0.83) | HCKSRCLCKTEKFLT3 | |
| SCHEMBL6463840 | 0.90 | HCK (0.82) | HCKSRCLCKTEKFLT3 | |
| SCHEMBL6459339 | 0.90 | HCK (0.82) | HCKSRCLCKTEKFLT3 | |
| SCHEMBL6459343 | 0.90 | HCK (0.82) | HCKSRCLCKTEKFLT3 | |
| SCHEMBL23873610 | 0.89 | HCK (0.81) | HCKSRCLCKTEKFLT3 | |
| SCHEMBL22845296 | 0.89 | HCK (0.80) | HCKSRCLCKTEKFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2878601-B1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | RIKEN (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-2878601-B1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | RIKEN (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-9604988-B2 | Agent for treating or inhibiting recurrence of acute myeloid leukemia | RIKEN (JP) | 2017-03-28 | — | — | US | disclosed |
| US-9604988-B2 | Agent for treating or inhibiting recurrence of acute myeloid leukemia | RIKEN (JP) | 2017-03-28 | — | — | US | disclosed |
| US-9604988-B2 | Agent for treating or inhibiting recurrence of acute myeloid leukemia | RIKEN (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2878601-A1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | Riken (JP) | 2015-06-03 | — | — | EP | disclosed |
| EP-2878601-A1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | Riken (JP) | 2015-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, BCOR, RUNX1 | HCK 2686/4885SRC 395/4885LCK 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.